NYSE · AGL
Agilon Health, Inc.
$85.94-$5.06 (-5.56%)
Agilon Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 35.4% below the high.
Loading market information…
NASDAQ · NAKA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nakamoto Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nakamoto Inc.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of -$0.49. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nakamoto Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nakamoto Inc. develops and invests in a global portfolio of Bitcoin-native companies. The company provides commercial and financial infrastructure for the capital markets. The company was formerly known as Kindly MD, Inc. and change its name to Nakamoto Inc. in January 2026. The company was incorporated in 2019 and is based in Nashville, Tennessee.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.17 | $579.70K |
|---|
| Q4 2024 | Mar 28, 2025 | -$0.17 | $603.89K |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.17 | $647.87K |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$85.94-$5.06 (-5.56%)
Agilon Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 35.4% below the high.
$7.97+$0.10 (+1.27%)
SOPHiA GENETICS S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
$14.64-$0.22 (-1.48%)
Delcath Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.96% below the high.
$18.50$0.00 (0.0%)
Simulations Plus, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.95% below the high.
$2.67+$0.13 (+5.12%)
Larimar Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.41% below the high.
$11.31+$0.38 (+3.43%)
Lyell Immunopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.88% below the high.
$12.74-$0.01 (-0.08%)
Amarin Corporation plc’s quoted price sits in the lower half of its reported 52-week range, 26.43% below the high.
$10.29-$0.36 (-3.38%)
DBV Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 60.71% below the high.
